Xianfeng Rao

Dr. Xianfeng Rao


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Medicine
Verified
Journal Article
Open access
XRXianfeng Rao
Xianfeng Rao
ZKZhengwen Kang
Zhengwen Kang
JCJianwei Chen
Jianwei Chen
CCChang Cai
Chang Cai
BWBo Wang
Bo Wang
QZQiusheng Zhang
Qiusheng Zhang
Background: Rosai–Dorfman disease is a benign lymphatic tissue proliferative disease with slow growth and is rarely observed in the clinic. Most of these patients present clinically with enlarged lymph nodes. In patients with spinal extranodal Rosai–Dorfman disease, which is even rare than the disease of lymph nodes, patients may experience numbness and weakness in the extremities. Case presentation: We report a 32-year-old male patient with multi-segmental spinal Rosai–Dorfman disease. On admission, his left fingers had been numb for 2 months. Over a 2-month period, the limb numbness progressed from the left to the right hand. The patient underwent resection of the lesion and internal fixation of the C2–C7 spine. The postoperative outcomes were satisfied and no recurrence was observed at 1-year follow-up. Conclusion: Spinal Rosai–Dorfman disease is a relatively rare tumor of which the pathogenesis is still unclear, and most patients have no specific clinical manifestations. Characteristic imaging findings can indicate this disease, however, a definitive diagnosis still depends on a pathological examination. Currently, total surgical resection of the tumor is a relatively effective and preferred treatment.

10 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
XRXianfeng Rao
Xianfeng Rao
MYMin Yang
Min Yang
HCHao Chen
Hao Chen
GLGuanhao Li
Guanhao Li
LWLi Wu
Li Wu
LTLei Teng
Lei Teng
Background: Gliomas are the most common primary malignant tumors of the central nervous system. Accurate preoperative grading is essential for individualized surgical planning and treatment selection; however, reliable non-invasive prediction tools integrating multimodal preoperative data remain limited. This study aimed to develop and internally validate an interpretable machine-learning model for non-invasive glioma grading. Methods: Clinical and imaging data from 400 patients with pathologically confirmed gliomas were retrospectively collected. Twenty-four preoperative variables were analyzed. The dataset was randomly divided into training and validation cohorts (7:3). Feature selection was performed using a combination of the Boruta algorithm and logistic regression analyses, followed by correlation filtering. Seventeen machine-learning algorithms were benchmarked using five-fold cross-validation, and the optimal model was evaluated in the independent validation cohort using ROC analysis, calibration assessment, precision–recall curves, and decision curve analysis. Model interpretability was examined using SHAP. Results: Eight key predictors were identified, including age, focal neurological deficits, midline shift, tumor laterality, tumor lobar location, enhancing tumor volume, and MRS-derived Cho/NAA and Cho/Cr ratios. The Random Forest model achieved an area under the ROC curve of 0.946 (95% CI: 0.902–0.989) in the validation cohort. Calibration analysis demonstrated reasonable agreement between predicted and observed outcomes, and the precision–recall curve yielded an average precision of 0.98. Decision curve analysis indicated net clinical benefit across relevant probability thresholds. Conclusions: A multimodal machine-learning model integrating clinical, structural imaging, and MRS-derived metabolic features was developed and internally validated for non-invasive preoperative glioma grading. The model showed good discrimination and calibration and provided individualized probability estimates, suggesting potential value for preoperative risk stratification. However, clinical deployment remains premature, and further external validation is required.

1 November 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
XRXianfeng Rao
Xianfeng Rao
GLGuanhao Li
Guanhao Li
MYMin Yang
Min Yang
HCHao Chen
Hao Chen
LWLi Wu
Li Wu
LTLei Teng
Lei Teng
Background: Postoperative pneumonia (POP) is a frequent complication after microsurgical clipping for aneurysmal subarachnoid hemorrhage (aSAH). Early preoperative identification of high-risk patients may facilitate timely preventive management. This study aimed to develop and internally validate an explainable machine learning model based on routinely available admission variables and translate it into a web-based risk calculator. Methods: This single-center retrospective study included 574 patients with aSAH who underwent microsurgical clipping between 2019 and 2024. Patients were randomly divided into training and internal validation cohorts at a ratio of 7:3. Feature selection was performed using Spearman correlation analysis and the Boruta algorithm. Thirteen machine learning algorithms were compared using five-fold cross-validation, and the optimal model was evaluated in the internal validation cohort. SHAP analysis was used to interpret model predictions. Results: Thirteen predictors were retained for model development. The random forest model implemented using ranger showed the best overall performance, achieving an AUC of 0.887 (95% CI, 0.838–0.936) in the internal validation set. Calibration was acceptable, with a Brier score of 0.135, and decision curve analysis suggested potential clinical net benefit. SHAP analysis identified D-dimer and Glasgow Coma Scale score as the leading contributors to model predictions. An interactive R Shiny calculator was developed for individualized POP risk estimation. Conclusions: An explainable ranger-based random forest model using readily available admission and preoperative variables showed good discrimination and acceptable calibration for predicting POP after aSAH clipping. The model may enable risk estimation before surgery without specialized testing and support early individualized risk stratification. External and prospective validation is required before broader clinical implementation.

9 February 2024 in Medicine
Verified
Journal Article
Open access
XRXianfeng Rao
Xianfeng Rao
ZKZhengwen Mm Kang
Zhengwen Mm Kang
JCJianwei Mm Chen
Jianwei Mm Chen
TWTong Mm Wang
Tong Mm Wang
MMMengyao Mm Ma
Mengyao Mm Ma
QZQiusheng Zhang
Qiusheng Zhang
Introduction: Cellular blue nevus is an uncommon neoplasm in the spine. Patient concerns: Here, we present a case of a 24 years old male with a 2 months history of numbness in the right upper limb and shoulder. Diagnosis: Cervical spine and subcutaneous tissue invasive cellular blue nevus. Interventions: The patient underwent C4 laminectomy and partial C3 and C5 laminectomy for total resection of the lesion. Histopathology revealed a nodular tumor with unclear boundaries, which was composed of heavily pigmented dendritic cells and more pigmented spindle cells. Outcomes: There was no recurrence during 3 years follow-up. Conclusion: Invasive cellular blue nevus of the spine can be wrongly diagnosed as spinal meningeal melanocytoma and meningeal melanoma due to its special cell behavior and rarity. Therefore, it is important to understand its pathological and clinical characteristics to avoid over-treatment.